RADIATION SEGMENTECTOMY:
Y-90 TARE AS CURATIVE TREATMENT FOR SMALL HCC
How high-dose Y-90 delivered to a single liver segment can achieve complete pathological ablation of small hepatocellular carcinoma — and why radiation segmentectomy is increasingly considered a curative-intent alternative to thermal ablation and surgery for appropriately selected patients.
analyticsAt a Glance
- check_circleRadiation segmentectomy delivers ≥190–200 Gy selectively to the tumour-bearing liver segment
- check_circlePublished complete pathological response rates of 25–35% — comparable to thermal ablation
- check_circleEnables treatment of tumours adjacent to major vessels where RFA/MWA carries prohibitive risk
- check_circleCancerFax coordinates radiation segmentectomy at specialist Y-90 centres in China and India
What Is Radiation Segmentectomy?
Radiation segmentectomy is a technique that deliberately concentrates the Y-90 injection into one or two Couinaud liver segments containing the target HCC — delivering an ablative radiation dose (≥190–200 Gy) specifically to that segment while largely sparing the remainder of the liver. The term 'segmentectomy' reflects the anatomical analogy to surgical segmental resection — both achieve ablation of a defined liver segment, but radiation segmentectomy does so without incision, general anaesthesia, or post-operative recovery.
“Radiation segmentectomy is the closest thing interventional oncology has to a non-surgical resection — ablating a defined liver segment from the inside.”
What Makes It Different From Standard TARE
Standard lobar or whole-liver TARE distributes microspheres across a large liver territory to control multiple lesions — at moderate absorbed dose to the tumour. Radiation segmentectomy concentrates microspheres into a small territory with the intent to ablate a single tumour completely — at very high absorbed dose, accepting deliberate ischaemic necrosis of the treated segment.
The Dose Threshold
The transition from 'disease control' to 'ablation' in TARE occurs around 190–200 Gy absorbed dose to the tumour. Below this threshold, tumour cells survive in varying proportions. Above it, complete pathological necrosis is achievable in a substantial proportion of patients. Delivering >200 Gy selectively to a small segment requires precise partition model dosimetry and selective segmental catheterisation.
Radiation Segmentectomy Outcomes — Clinical Data
Published data from the leading radiation segmentectomy cohort studies — primarily from North American and European expert centres with defined dosimetry protocols.
Radiation Segmentectomy vs Thermal Ablation — Complete Pathological Response (HCC ≤3 cm)
Complete pathological response (CPR) in explanted liver specimens from patients bridged to transplant. Source: Vouche et al., Hepatology 2014; Salem et al., multiple series.
- CPR: radiation segmentectomy (>190 Gy)~25–35%
- CPR: thermal ablation (RFA/MWA)~20–30%
5-Year Overall Survival — Radiation Segmentectomy HCC Cohort
5-year OS data from expert Y-90 centre radiation segmentectomy series for early HCC. Source: Gabr et al., Hepatology 2021 and pooled expert centre data.
- 5-year OS: radiation segmentectomy (early HCC)~70–75%
- 5-year OS: surgical resection (early HCC, comparable)~60–75%
Radiation Segmentectomy — Eligibility Criteria
Radiation segmentectomy is appropriate for a specific subset of early HCC patients — those where its ablative capability addresses a clinical challenge that surgery or thermal ablation cannot.
| Criterion | Ideal Candidate | Requires Assessment | Contraindication |
|---|---|---|---|
| Tumour size | ≤3–4 cm, solitary | 3–5 cm with good segmental anatomy | Multifocal or >5 cm — standard lobar TARE preferred |
| Tumour location | Perivascular (adjacent to major vessels) | Any anatomically distinct segment | Infiltrative or diffuse distribution |
| Liver function | Child-Pugh A5–A6 | Child-Pugh B7 | Child-Pugh C or B8+ |
| Future liver remnant | Adequate FLR volume after segment ablation | FLR borderline — volume calculation required | Insufficient FLR after planned segmentectomy |
| Segmental arterial supply | Well-defined segmental artery identifiable | Variant anatomy amenable to super-selective catheterisation | Shared segment blood supply with critical normal structures |
| Treatment intent | Bridging to transplant; curative locoregional ablation | Downstaging before resection | Palliative intent — standard lobar TARE preferred |
Radiation Segmentectomy vs Thermal Ablation vs Surgical Resection
For small HCC, three curative-intent approaches are available. Radiation segmentectomy occupies a distinct niche between thermal ablation and surgery.
Radiation Segmentectomy
- Effective for perivascular tumoursMajor hepatic vessel proximity is a contraindication for RFA (heat sink effect) but is specifically suited to radiation segmentectomy — high-dose Y-90 is not affected by vessel cooling.
- Treats the entire arterially supplied segmentRadiation segmentectomy ablates not just the visible tumour but the entire arterially defined segment — addressing satellite lesions and microinvasion beyond the imaging-visible tumour.
- No ablation zone size limitationRFA and MWA produce a defined ablation zone limited by probe geometry and tissue conductivity. Y-90 dose follows arterial distribution — reaching the full extent of the tumour-feeding segment.
- No thermal damage to adjacent structuresRadiation segmentectomy does not produce the thermal spread that can damage adjacent bile ducts, diaphragm, or bowel when ablating centrally located or subcapsular tumours.
Thermal Ablation (RFA/MWA)
- Faster and simpler procedurallyRFA or MWA is performed percutaneously or laparoscopically in 1–2 hours with immediate local response — no pre-treatment mapping session, no dosimetry, no Y-90 supply chain.
- Immediate treatment — no manufacturing waitThermal ablation is performed in a single session; radiation segmentectomy requires a planning session 1–2 weeks before treatment.
- Wider availability globallyRFA and MWA are available at virtually every interventional radiology unit worldwide — radiation segmentectomy requires a specialist Y-90 centre with partition model dosimetry expertise.
- Well-established long-term recurrence dataThermal ablation has decades of outcome data, including long-term recurrence surveillance — radiation segmentectomy OS data beyond 5 years is still accumulating.
Radiation Segmentectomy — Key Numbers
The critical quantitative benchmarks that define the curative potential of radiation segmentectomy for small HCC.
- ≥200 GyTumour absorbed dose target for complete pathological responseThe threshold at which complete pathological necrosis is achievable in a substantial proportion of patients — requiring partition model dosimetry for reliable delivery.
- ~30%Complete pathological response rate at explant (bridging to transplant series)Published complete response rates from liver explant pathology — the gold-standard evidence for radiation segmentectomy ablative efficacy.
- ~70–75%5-year overall survival in expert centre radiation segmentectomy cohortsOutcomes approaching those of surgical resection — supporting radiation segmentectomy as a true curative-intent strategy for appropriately selected patients.
More from the TARE / Y-90 Resource Library
Continue exploring Y-90 radioembolization — from the clinical evidence in HCC to radiation lobectomy and portal vein thrombosis.
Frequently Asked Questions: Radiation Segmentectomy for HCC
How does radiation segmentectomy compare to surgical resection for small HCC?
Published 5-year OS data from expert radiation segmentectomy cohorts (approximately 70–75%) is broadly comparable to surgical resection for early HCC in cirrhotic patients (typically 60–75%), though direct randomised comparison does not yet exist. Radiation segmentectomy has the advantage of no surgical risk, no anaesthesia, shorter recovery, and ability to treat patients with portal hypertension or marginal liver function where surgery would be unsafe. However, surgical resection provides a definitive pathological specimen and is the standard approach when technically feasible in patients with sufficient liver reserve.
Will the treated liver segment regrow after radiation segmentectomy?
No. The deliberate ischaemic and radiation injury to the treated segment causes its permanent atrophy — this segment does not regenerate. The remaining liver compensates through hypertrophy of adjacent segments. The volume of liver atrophied by radiation segmentectomy is relatively small (one or two of the 8 Couinaud segments), and this volume loss is well tolerated in patients with sufficient future liver remnant. The volumetric redistribution that follows is actually exploited therapeutically in radiation lobectomy, where intentional lobar atrophy drives contralateral hypertrophy before planned surgical resection.
Can radiation segmentectomy be repeated if the HCC recurs?
Yes, in selected patients. Recurrence in a different liver segment from the originally treated one can be addressed with repeat radiation segmentectomy provided: adequate residual liver volume, preserved liver function (Child-Pugh A), acceptable lung shunt fraction at re-mapping, and technically accessible arterial anatomy. Recurrence within the previously treated segment is rare after complete pathological response but, if it occurs, salvage with repeat segmentectomy, thermal ablation, or escalation to transplant listing should be discussed in an MDT forum.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is Radiation Segmentectomy an Option for Your HCC?
CancerFax reviews your HCC imaging, liver function, and prior treatment history to assess radiation segmentectomy eligibility and coordinates access at specialist Y-90 interventional oncology centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.